Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.
A number of other analysts also recently weighed in on MNPR. Morgan Stanley increased their target price on shares of Monopar Therapeutics from $130.00 to $133.00 and gave the company an “overweight” rating in a research report on Monday, November 16th. Cantor Fitzgerald upgraded shares of Monopar Therapeutics from a “neutral” rating to an “overweight” rating and set a $119.00 price target on the stock in a research report on Thursday, November 12th. Barclays reaffirmed an “overweight” rating and issued a $145.00 price objective (up from $128.00) on shares of Monopar Therapeutics in a research note on Friday, September 11th. BTIG Research reiterated a “buy” rating on shares of Monopar Therapeutics in a research report on Thursday, November 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Thursday, October 15th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $123.12.
Get Our Latest Research Report on MNPR
Monopar Therapeutics Stock Performance
Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.72) EPS for the quarter, hitting analysts’ consensus estimates of ($0.72). Sell-side analysts predict that Monopar Therapeutics will post -2.64 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, Director Christopher Starr sold 8,400 shares of the company’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $78.50, for a total transaction of $659,400.00. Following the sale, the director owned 5,173 shares in the company, valued at $406,080.50. This represents a 61.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kim Tsuchimoto sold 4,090 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $111.39, for a total value of $455,585.10. Following the sale, the director directly owned 7,396 shares of the company’s stock, valued at $823,840.44. This represents a 35.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 51,920 shares of company stock valued at $4,527,913 over the last 90 days. 9.70% of the stock is owned by company insiders.
Hedge Funds Weigh In On Monopar Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the business. American Century Companies Inc. grew its position in shares of Monopar Therapeutics by 127.1% during the 3rd quarter. American Century Companies Inc. now owns 5,606 shares of the company’s stock worth $447,000 after buying an additional 3,137 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Monopar Therapeutics by 443.8% in the 3rd quarter. Goldman Sachs Group Inc. now owns 87,877 shares of the company’s stock valued at $7,001,000 after acquiring an additional 71,716 shares in the last quarter. State Street Corp increased its stake in shares of Monopar Therapeutics by 24.1% in the 3rd quarter. State Street Corp now owns 229,771 shares of the company’s stock valued at $18,306,000 after acquiring an additional 44,669 shares in the last quarter. Meeder Asset Management Inc. increased its stake in shares of Monopar Therapeutics by 18.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 1,651 shares of the company’s stock valued at $132,000 after acquiring an additional 262 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of Monopar Therapeutics during the 2nd quarter valued at $7,124,000. 1.83% of the stock is currently owned by institutional investors.
Monopar Therapeutics Company Profile
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.
Featured Articles
- Five stocks we like better than Monopar Therapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
